Kabi ships alternative to Takeda’s Velcade

Fresenius Kabi has realised plans to launch its 505(b)(2) hybrid bortezomib 3.5mg/vial injectable in the US, after announcing the availability of the “first and only” alternative to Takeda’s Velcade (bortezomib) intravenous injectable.